Trial · NCT07903857
SND002 Cell Injection in Participants With Advanced Malignant Solid Tumors
NCT07903857, Phase 1, Not yet recruiting, Guizhou Sinorda Pharmaceutical Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. SND002 Cell Injection in Participants With Advanced Malignant Solid Tumors. Trials, record NCT07903857. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07903857
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- SND002 Cell Injection in Participants With Advanced Malignant Solid Tumors
- NCT number
- NCT07903857
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 78 participants, estimated
- Lead sponsor
- Guizhou Sinorda Pharmaceutical Co., Ltd.
- Conditions
- Colorectal Neoplasms, Stomach Neoplasms, Solid Tumor Malignancies
- Interventions
- SND002 Cell Injection
- First posted
- 2026-10-29
- Last updated
- 2026-11-04
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities | From the start of lymphodepleting chemotherapy (Day -5) through Day 28 after SND002 Cell Injection infusion | Safety was assessed by treatment-emergent adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 6.0, serious adverse events, dose-limiting toxicities, clinical laboratory tests (hematology, serum chemistry, coagulation, urinalysis, cardiac enzymes, troponin, and thyroid function), 12-lead electrocardiogram, physical examination, and vital signs. |
| Primary | Recommended cell-dose range (cells) for further study as determined by the Safety Review Committee | Through completion of the dose-escalation part (Part A) | The recommended dose was defined as the cell-dose range selected for the expansion part on the basis of dose-limiting toxicities observed during dose escalation under a modified 3+3 design. |
| Primary | Percentage of participants with an objective response (complete response or partial response) assessed by RECIST 1.1 | From SND002 Cell Injection infusion through Week 24 | Objective response rate was defined as the proportion of participants whose best overall response was complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), as assessed by the investigator. |
| Primary | Percentage of participants with disease control (complete response, partial response, or stable disease) assessed by RECIST 1.1 | From SND002 Cell Injection infusion through Week 24 | Disease control rate was defined as the proportion of participants whose best overall response was CR, PR, or stable disease (SD) according to RECIST 1.1. Stable disease was required to persist for at least 6 weeks. |
| Secondary | Progression-free survival (time from infusion to progression or death from any cause) assessed by the investigator according to RECIST 1.1 | From infusion until disease progression or death from any cause, whichever occurs first (up to 1 year) | |
| Secondary | Percentage of participants alive and progression-free at 1 year after infusion | At 1 year after infusion | |
| Secondary | Overall survival (time from infusion to death from any cause) | From infusion until death from any cause (up to 1 year) | |
| Secondary | Percentage of participants alive at 1 year after infusion | At 1 year after infusion | |
| Secondary | Time to response in participants with an objective response | From infusion to first documentation of CR or PR (up to 1 year) | |
| Secondary | Duration of response in participants with an objective response | From first documentation of CR or PR to first documentation of progression or death, whichever occurs first (up to 1 year) |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07903857
GET https://conductscience.org/api/trials/v1/NCT07903857/registered